Syndax Pharmaceuticals has been granted a patent for inhibitors targeting the interaction of menin with MLL and MLL fusion proteins for treating cancer and other diseases. The compound of Formula 0 is claimed for pharmaceutical use. GlobalData’s report on Syndax Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Syndax Pharmaceuticals, Cancer treatment biomarkers was a key innovation area identified from patents. Syndax Pharmaceuticals's grant share as of February 2024 was 18%. Grant share is based on the ratio of number of grants to total number of patents.
A recently granted patent (Publication Number: US11919901B2) discloses a compound of Formula 0, with various specific configurations outlined in the claims. The compound is designed for the treatment of leukemia by minimizing hERG binding, with potential applications in inhibiting the interaction between menin and MLL. The patent also covers pharmaceutical compositions containing the compound and methods for treating leukemia, including specific subtypes such as NPM1-mutated acute myeloid leukemia.
Furthermore, the patent extends to the use of the compound in preventing or treating diseases associated with menin expression, activity, and function, particularly focusing on leukemia. The therapeutic approach involves administering the compound to individuals requiring treatment, showcasing its potential in addressing a wide range of leukemia types, from acute lymphocytic leukemia to chronic myelogenous leukemia. The compound's versatility in targeting various forms of leukemia highlights its significance in the field of oncology and underscores its potential impact on improving treatment outcomes for patients with these conditions.
To know more about GlobalData’s detailed insights on Syndax Pharmaceuticals, buy the report here.
See Also:
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
